Description
Title: Omalizumab, a humanized monoclonal anti-IgE that has been combined, is a new test for clinical use of lek.
Abstract: The monoclonal anti-IgE antibody omalizumab prevents or lessens allergic reaction and asthma symptoms by preventing IgE from binding to effector cell receptors. Omalizumab is currently approved for the treatment of patients with severe persistent uncontrolled asthma in the USA and the European Union, including Poland. It significantly lowers symptom intensity, enhances quality of life, and reduces hospitalizations, emergency room visits, and asthma exacerbations. However, omalizumab acts more broadly; when administered subcutaneously, it has a systemic impact. Review of studies and case studies on the use of omalizumab in new indications are presented in this article. There are also some of the authors’ personal experiences in this area.
Keywords: omalizumab, atopic diseases, allergic rhinitis, atopic dermatitis, urticaria
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Advances in Respiratory Medicine
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.